Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer

Metastatic prostate cancer is treated with drugs that antagonize androgen action but most patients progress to a more aggressive form of the disease called castration-resistant prostate cancer, driven by elevated expression of the androgen receptor. Here we characterize the diarylthiohydantoins RD16...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Tran, Chris, Ouk, Samedy, Clegg, Nicola J., Chen, Yu, Watson, Philip A., Arora, Vivek, Wongvipat, John, Smith-Jones, Peter M., Yoo, Dongwon, Kwon, Andrew, Wasielewska, Teresa, Welsbie, Derek, Chen, Charlie, Higano, Celestia S., Beer, Tomasz M., Hung, David T., Scher, Howard I., Jung, Michael, Sawyers, Charles L.
Format: Artigo
Idioma:Inglês
Publicat: 2009
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2981508/
https://ncbi.nlm.nih.gov/pubmed/19359544
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/science.1168175
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars